Surmodics IVD Launches Breakthrough StabilBlock® Immunoassay Stabilizer
August 01 2016 - 7:05AM
Business Wire
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical
components for in vitro diagnostic (IVD) tests and microarrays, has
announced the launch and immediate availability of StabilBlock®,
its most advanced Immunoassay Stabilizer. StabilBlock Immunoassay
Stabilizer is the best available reagent for reducing non-specific
binding to boost immunoassay signal-to-noise ratios.
Surmodics offers a family of immunoassay stabilizers, which
preserve the conformation and activity of dried proteins on a wide
range of surfaces, keeping antibodies and antigens at peak
performance for long durations. At the same time, the blocking
mechanisms in these reagents reduce non-specific binding of
interfering proteins to maximize assay sensitivity. With
StabilBlock, StabilCoat® and StabilGuard® Immunoassay Stabilizers,
the company now offers three options to assay developers with a
combination of blocking efficacy and long-term dried stability that
is unmatched in the industry.
“As part of our commitment to being the premier provider of IVD
assay components to improve performance and manufacturability of
immunoassays, we continue to advance our offerings to meet the
needs of our customers,” said Joe Stich, vice president and general
manager of Surmodics IVD, the company’s In Vitro Diagnostics
business. “We recognize that each assay has its own blocking
requirements and our expanded portfolio of Immunoassay Stabilizers
will enable assay developers to achieve the best results for each
application.”
Surmodics IVD products immediately improve assay performance and
manufacturability of assays by lowering backgrounds, increasing
signal generation and providing longer shelf lives for immunoassay
production. The addition of StabilBlock Immunoassay Stabilizer
augments the company’s leading portfolio of products,
including:
- The StabilZyme® family provides
unparalleled long-term stability of protein conjugates at working
strength concentrations. Surmodics formulations for HRP conjugates,
AP conjugates and general protein applications ensure that assay
developers have a complete set of tools to address the labile
nature of each protein of interest.
- BioFX® TMB substrate family outperforms
competitors for low background, stability and sensitivity with a
variety of kinetic rate substrates. The one-component formulations
provide optimal signal generation and longer shelf lives.
- Assay Diluent (Protein-Free) normalizes
the sample matrix and reduces interference to ensure that
analyte-specific signal is generated within an assay system.
About Surmodics, Inc.Surmodics is the global leader in
surface modification technologies for intravascular medical devices
and a leading provider of chemical components for in vitro
diagnostic (IVD) tests and microarrays. Following two recent
acquisitions of Creagh Medical and NorMedix, the company is
executing a key growth strategy for its medical device business by
expanding to offer total intravascular product solutions to its
medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly
increase the value it offers with highly differentiated
intravascular solutions designed and engineered to meet the most
demanding requirements.
With this focus on offering total product
solutions, Surmodics’ mission remains to improve the detection and
treatment of disease. Surmodics is headquartered in Eden Prairie,
Minnesota. For more information about the company, visit
www.surmodics.com. The content of Surmodics’ website is not part of
this press release or part of any filings that the company makes
with the SEC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160801005190/en/
Surmodics, Inc.Andy LaFrence, 952-500-7000Vice President of
Finance and Chief Financial Officer
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2023 to Apr 2024